Analyst Price Targets — BDTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 16, 2026 11:54 am | Kelsey Goodwin | Piper Sandler | $8.00 | $2.67 | TheFly | Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler |
| October 15, 2025 8:31 pm | Laura Prendergast | Stifel Nicolaus | $8.00 | $4.14 | TheFly | Black Diamond Therapeutics resumed with a Buy at Stifel |
| September 3, 2025 8:15 pm | Brad Canino | Guggenheim | $8.00 | $2.88 | TheFly | Black Diamond Therapeutics initiated with a Buy at Guggenheim |
| July 31, 2024 8:18 am | Laura Prendergast | Raymond James | $20.00 | $5.91 | TheFly | Black Diamond Therapeutics initiated with an Outperform at Raymond James |
| June 3, 2024 8:52 am | Joseph Calanzaro | Piper Sandler | $12.00 | $4.78 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Black Diamond Therapeutics (BDTX) |
| May 16, 2024 6:12 am | Robert Burns | H.C. Wainwright | $11.00 | $5.44 | TheFly | Black Diamond price target lowered to $11 from $12 at H.C. Wainwright |
| April 8, 2024 7:07 am | Robert Driscoll | Wedbush | $16.00 | $5.06 | StreetInsider | Black Diamond Therapeutics (BDTX) PT Raised to $16 at Wedbush |
| March 18, 2024 6:38 am | Raghuram Selvaraju | H.C. Wainwright | $12.00 | $4.70 | StreetInsider | Black Diamond Therapeutics (BDTX) PT Raised to $12 at H.C. Wainwright |
Latest News for BDTX
Here is how Black Diamond (BDTX) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BDTX, LUMN, ADEA, ACRE and TACT have been added to the Zacks Rank #1 (Strong Buy) List on January 9th, 2026.
Shares of Black Diamond Therapeutics, Inc. (NASDAQ: BDTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have assigned a buy
Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Volatility and Risk Black Diamond Therapeutics
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BDTX.
U.S. House Trading
No House trades found for BDTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.